EBITDA $100M is def "possible", but you've not mentioned a timeframe.
Let's just get to +$1 first - without removing items that shouldn't be removed.
Derm needs to at least hold fat. The first 3 months were REALLY strong, month 4, not so much.
Management are doing the right 'things', but if someone is questioning why the share price is taking a breather; let's be realistic, we need to see continual and sustained growth as revenue needs to get well above $400m before we are cashflow POS and EBITDA +
Ann: Mayne Pharma presentation at JP Morgan Healthcare Conference, page-21
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.47 |
Change
-0.010(0.22%) |
Mkt cap ! $381.1M | |||
| Open | High | Low | Value | Volume |
| $4.45 | $4.53 | $4.45 | $81.52K | 18.22K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 457 | $4.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.47 | 954 | 5 |
View Market Depth
| Last trade - 10.42am 05/07/2024 (20 minute delay) ? |
| MYX (ASX) Chart |